Iktos vs Variational AI (2026)

Iktos and Variational AI generate small molecules against a research team's desired properties. Iktos connects design software to retrosynthesis and laboratory automation; Variational AI applies Enki through collaborations organized around target profiles and resulting compound rights. Iktos Makya generates structures with synthetic accessibility and a target product profile built into the process. Spaya proposes routes from commercially available starting materials, and Iktos Robotics extends into synthesis, purification and testing. Chemists select compounds at the design stage, though where human decisions sit in the downstream laboratory automation is not described. Licensable software sits alongside discovery collaborations and internal preclinical programs. Variational AI's Enki proposes molecules against potency, unwanted activity and chemical property goals, then supports optimization around a chosen scaffold. Chemists select candidates for laboratory work. In a Life Chemicals project, 19 selected compounds were synthesized and five showed dual kinase activity. That experimental result supports a specific discovery task, not success across every target in the broader catalog. Iktos fits chemistry teams wanting design and synthesis planning tools, with a possible connection to automated laboratory work. Variational AI fits biotechnology and pharmaceutical partners structuring a target focused collaboration around generated compounds and subsequent testing. Both operate in discovery chemistry, where computational proposals become useful through selection, synthesis and experimental validation.